Membranous Nephropathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Although it is one of the leading causes of nephrotic syndrome in nondiabetic adults, there are currently no approved therapies for pMN. The treatment landscape is gradually shifting from alkylating agent-based regimens and calcineurin inhibitors toward B-cell-targeted therapies. Over the 2025-2035 period, we expect the pMN therapy market to transform through the launch of several emerging therapies. Next-generation CD20 and plasma-cell targeted agents, BAFF- / APRIL-targeted therapies, and BTK inhibitors are among the leading candidates positioned to achieve the first regulatory approval for pMN.
Questions answered
- How do physicians use current off-label therapies to treat the disease?
- What are the KOLs’ views on late-phase candidates obinutuzumab (Roche), felzartamab (Biogen), povetacicept (Vertex Therapeutics), and zanubrutinib (BeOne Medicines)?
- How will emerging therapies influence the treatment landscape and affect prescribing decisions?
- What are the pMN therapy market’s key drivers and constraints, and how will the market evolve over the forecast period?
- What are the unmet needs in pMN, and how likely are they to be fulfilled during the forecast period?
Geography: United States, EU5, Japan
Primary research: Country-specific interviews with thought-leading nephrologists. Survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed incidence of pMN by country, clinically and market-relevant drug-treatable populations
Forecast: 10-year, annualized, drug-level sales and patient share of key membranous nephropathy therapies through 2035, segmented by brands / generics and epidemiological subpopulations
Drug treatments: Coverage of key current and late-phase emerging therapies
Product description
Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
- Gauge the commercial outlook and impact of key market events.
Table of contents
- Membranous Nephropathy - Landscape & Forecast - Disease Landscape & Forecast (G7)
- Executive Summary
- Key Updates
- Market Forecast
- Disease Context
- Epidemiology
- Current Treatment
- Emerging Therapies
- Appendix
- Executive Summary
